Daewoong & Samsung Bioepis’ exclusive sales agreement of Samfenet in Korea

Published: 2017-12-20 16:03:14

Updated: 2017-12-20 16:03:14

Daewoong Pharmaceutical will jump into the ‘anticancer drug field.’

Daewoong Pharmaceutical announced the company signed an exclusive sales agreement of ‘Samfenet,’ an anticancer biosimilar, in Korea with Samsung Bioepis on the 15^th. Under the agreement, the Daewoong Pharmaceutical’s anticancer lineup has now included a biosimilar(SB3), a chemical substance(Supect) and supplements(Instanyl, Ma...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.